Axonics Modulation Technologies Inc. (AXNX) Reports Q3 Loss of $2.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Axonics® Announces Third Quarter 2018 Financial Results and Operational Update
December 11, 2018 4:00 PM ESTIRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (SNM) devicesfor the treatment ofurinary and bowel dysfunction, reported today financial results for the quarter endedSeptember30, 2018 and provided an update on operational initiatives.
Recent Business Highlights
On November... More